| P2093 | author name string | A Hochhaus | |
| | F Heidel | |
| P2860 | cites work | A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis | Q33399980 |
| | Ruxolitinib versus standard therapy for the treatment of polycythemia vera. | Q33420037 |
| | Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both | Q38725723 |
| | Impact of tofacitinib treatment on human B-cells in vitro and in vivo | Q39237235 |
| | JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms | Q41138516 |
| | JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells | Q41160178 |
| | Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib. | Q46891342 |
| | Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function. | Q54254821 |
| | Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China | Q83767469 |
| | Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease | Q87635679 |
| | Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial | Q90181685 |
| | Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis | Q90249953 |
| | JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation | Q90340948 |
| | Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation | Q92528596 |
| | Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study | Q92940643 |
| | Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease | Q93152425 |
| | HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19 | Q94568423 |
| | An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study | Q94919190 |
| | Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients | Q95603823 |
| | Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study | Q96032684 |
| | SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine "storm" and risk factor for damage of hematopoietic stem cells | Q96127261 |
| | The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation | Q96230236 |
| P921 | main subject | ruxolitinib | Q7383611 |
| | SARS-CoV-2 | Q82069695 |
| P577 | publication date | 2020-06-11 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation | |